Table 3 Univariate analysis for local control (LC) and overall survival (OS)

Age (per 10-y increase)

0.95 (0.80-1.15)

0.617

0.93 (0.80-1.11)

0.428

Gender (female vs. male)

0.66 (0.34-1.19)

0.177

0.53 (0.33-0.83)

0.005*

Performance status (0–1 vs. ≥ 2)

1.19 (0.52-3.43)

0.703

0.86 (0.50-1.58)

0.619

Tumor origin (primary lung cancer vs. metastatic lung tumors)

0.48 (0.27-0.87)

0.017*

0.53 (0.34-0.84)

0.007*

History of other malignancies (yes vs. no)

0.70 0.38-1.21)

0.212

0.83 (0.56-1.20)

0.331

Pack-year smoking (≥ 37.5 vs. < 37.5)

1.38 (0.77-2.51)

0.266

0.85 (0.57-1.26)

0.426

Operability (operable vs. inoperable)

0.68 (0.38-1.19)

0.185

0.76 (0.52-1.12)

0.173

FEV1, % of predicted (≥ 92% vs. < 92%)

1.01 (0.49-2.05)

0.972

0.84 (0.51-1.36)

0.494

Tumor diameter (per 1 cm increase)

1.87 (1.35-2.57)

<0.001*

1.70 (1.33-2.16)

<0.001*

SUVmax (≥ 5.9 vs. < 5.9)

2.21 (1.02-5.03)

0.042*

2.12 (1.26-3.64)

0.004*

Date of treatment (2001–2005 vs. 2006–2011)

1.91 (1.11-3.39)

0.019*

1.36 (0.93-1.99)

0.106

Prescription dose (BED10: > 105 Gy vs. ≤ 105 Gy)

0.56 (0.32-0.96)

0.038*

0.94 (0.65-1.37)

0.760

Radiation pneumonitis (≥ 2 vs. < 2)

0.85 (0.34-1.78)

0.689

0.72 (0.40-1.22)

0.225